Journals / İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi / 2012 / Cilt: 2 - Sayı: 1

Toxic epidermal necrolysis-Stevens Johnson overlap syndrome: A case report

Toksik epidermal Nekroliz-Stevens Johnson overlap sendromu: Bir olgu sunumu

Pages
32–35
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

With this case report we pointed to a life-threatening side effect of these drugs, and wanted to indicate that IVIG therapy is among effective, and safe therapeutic alternatives.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Toxic epidermal necrolysis is seen rarely.
📊
Key Findings & Data:In this article, upper respiratory tract infection developed in male patients of 18 months beginning from 15. days of amoxycilline -clavulanic acid, terbutaline, and ibuprofen treatment with manifestations of skin rashes, and subsequent toxic epidermal necrolysis-Steven Johnson overlap syndrome. the first day follow-up and the three-day (400 mg/kg/day), Intravenous immunoglobulin (IVIG) therapy starting from the first day of follow-up, and maintained for 3 days at a dose of 400 mg/kg/day resulted in a dramatic improvement.
💡
Conclusion & Impact:With this case report we pointed to a life-threatening side effect of these drugs, and wanted to indicate that IVIG therapy is among effective, and safe therapeutic alternatives.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Toxic epidermal necrolysis is seen rarely. It generally develops secondary to drugs and sometimes infection. It is characterized by peeling of the skin. Morbidity and mortality is very high. There is no definitive consensus about the treatment of toxic epidermal necrolysis. In this article, upper respiratory tract infection developed in male patients of 18 months beginning from 15. days of amoxycilline -clavulanic acid, terbutaline, and ibuprofen treatment with manifestations of skin rashes, and subsequent toxic epidermal necrolysis-Steven Johnson overlap syndrome. the first day follow-up and the three-day (400 mg/kg/day), Intravenous immunoglobulin (IVIG) therapy starting from the first day of follow-up, and maintained for 3 days at a dose of 400 mg/kg/day resulted in a dramatic improvement. With this case report we pointed to a life-threatening side effect of these drugs, and wanted to indicate that IVIG therapy is among effective, and safe therapeutic alternatives.

Özet

Toksik epidermal nekrolizis seyrek olarak görülür. Genellikle ilaçlar ve bazen de infeksiyonlara bağlı olarak gelişir. Derinin soyulması ile karekterizedir. Morbidite ve mortalitesi çok yüksektir. Bugün halen tedavisi konusunda kesin bir fikir birliğinin olmadığı bir klinik tablodur. Bu makalede, 18 aylık erkek hastada üst solunum yolu infeksiyonuna yönelik olarak amoksislin klavulonik asit, terbutalin, ibuprofen kullanımı sırasında tedavinin on beşinci gününde başlayan ateş, deri döküntüleri ve sonrasında toksik epidermal nekrolizis-steven Johnson overlap tablosu gelişen olgu sunulmuştur. Olgunun izleminin birinci gününde başlanılan ve üç gün verilen (400 mg/kg/ gün) intravenöz immünglobulin (IVIG) tedavisi ile dramatik düzelme sağlanmıştır. Bu olgu nedeniyle ilaçların yaşamı tehdit edebilen bir yan etkisine dikkat çekilerek IVIG tedavisinin etkili ve güvenilir bir alternatif olarak tedavi seçenekleri arasında olduğunu belirtmek istedik.

🔖

Cite This Article

KANGAL, H., GÜLEZ, P., HEKİMOĞLU, Ü., HIZARCIOĞLU, M. (2012). Toxic epidermal necrolysis-Stevens Johnson overlap syndrome: A case report. İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi, Cilt: 2 - Sayı: 1, 32–35. https://ajindex.com/articles/219753

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956
  2. http://dx.doi.org/10.1111/j.1365-2133.1956.tb12766.x PMid:13374196 2. Becker DS. Toxic epidermal necrolysis. Lancet 1998
  3. http://dx.doi.org/10.1016/S0140-6736(97)11369-1 3. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001
  4. PMid:11405768 4. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990
  5. http://dx.doi.org/10.1001/archderm.1990.01670250049006 PMid:2404462 5. Rutter A, Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune disease. J Am Acad Dermatol 2001
  6. http://dx.doi.org/10.1067/mjd.2001.112325 PMid:11369915 6. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nat Med 1996
  7. http://dx.doi.org/10.1038/nm0396-317 PMid:8612231 7. Viard I, Wehrli P. Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998
  8. http://dx.doi.org/10.1126/science.282.5388.490 PMid:9774279 8. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literatüre. Pediatrics 2003
  9. 112(6 Pt 1):1430-1436. http://dx.doi.org/10.1542/peds.112.6.1430 PMid:14654625 9. Revuz J, Penso D. Toxic epidermal necrolysis: clinical findings and prognostic factors in 87 patients. Arch Dermatol 1981
  10. http://dx.doi.org/10.1001/archderm.1987.01660330071012 PMid:3632000 10. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001
  11. http://dx.doi.org/10.1056/NEJMra993360 PMid:11547745 11. Amato GM, Travia A, Ziino O. The use of intravenous high-dose immunoglobulins (IVIG) in a case of Stevens-Johnson syndrome. Pediatr Med Chir 1992
  12. PMid:1488317 12. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nat Med 1996
  13. http://dx.doi.org/10.1038/nm0396-317 PMid:8612231 13. Viard I, Wehrli P. Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998
  14. http://dx.doi.o